Ziopharm’s TCR-T Program Pushed Back to H1 2022; Ziopharm Sheds Over 50% of Its Workforce

On Monday, September 27, Ziopharm announced (press release) that they have reduced their staffing levels by over 50% (eliminating 60 positions) while extending their cash runway into H1 2023. Additionally, management confirmed that the first patient from the Ph1/2 TCR-T Library trial is expected to be dosed in H1 2022. Below, Celltelligence provides insights on Ziopharm’s TCR-T program delay, in-house manufacturing strategy, and if the company’s latest measures will regain shareholders’ confidence.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.